港股異動丨敏華控股(1999.HK)大漲近7% 中期同比增長6.07%
格隆匯11月18日丨敏華控股(1999.HK)盤初直線拉昇,現升6.87%,報5.6港元,暫成交2192萬港元,最新總市值213.6億港元。

敏華控股日前公佈,截至2019年9月30日止六個月股東應占期內溢利7.06億港元,同比增長6.07%。由於人民幣兑美元貶值亦提高出口銷售利潤率。直接成本與上年同期相比減少約2.2%。
中金公司點評稱,敏華控股內銷持續向好,外銷迎來向上拐點,重申TOPPICK。廣發證券則稱,內銷提速、盈利改善,下半財年北美市場好轉在即。維持公司“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.